论文部分内容阅读
目的对恶性肿瘤风险指数(RMI)在卵巢恶性肿瘤术前诊断中的作用进行探讨。方法对150例卵巢肿瘤患者的临床资料进行回顾分析,患者术前均进行血清癌胚抗原(CA)125、超声分数、绝经状态及RMI预测,对比分析三者阳性值、特异性及敏感性。结果在卵巢肿瘤良恶性术前预测方面,超声诊断、绝经状态的预测结果比较差异有统计学意义(P<0.05)。基于RMI 200为标准,检查敏感性为87.5%,特异性为84.6%,阳性值为81.5%;和其它指标相比,在预测卵巢肿瘤良恶性方面准确性更高。结论在卵巢肿瘤术前诊断中,RMI比血清CA125、超声分数的预测更为准确,且易操作,具有临床应用价值。
Objective To investigate the role of malignant tumor risk index (RMI) in the preoperative diagnosis of ovarian cancer. Methods Clinical data of 150 patients with ovarian tumors were retrospectively analyzed. Preoperative serum carcinoembryonic antigen (CA) 125, ultrasonic score, menopausal status and RMI were calculated. The positive, specificity and sensitivity of the three methods were compared. Results In the preoperative prediction of benign and malignant ovarian tumors, there were significant differences in the results of ultrasound diagnosis and menopause (P <0.05). Based on the RMI 200 standard, the test sensitivity was 87.5%, specificity was 84.6%, and the positive value was 81.5%. Accuracy in predicting benign and malignant ovarian tumors was higher than other indicators. Conclusion In the preoperative diagnosis of ovarian tumors, RMI is more accurate than serum CA125 and predicting the ultrasound score, and it is easy to operate and has clinical value.